PT-141

HormonesFDA-Approved

Overview

PT-141 (Bremelanotide, brand name Vyleesi®) is a synthetic melanocortin peptide and MC4 receptor agonist. It is FDA-approved for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. Unlike PDE5 inhibitors, it works through central nervous system pathways rather than vascular mechanisms.

Evidence Strength

🟢

Human Clinical Evidence

Supported by peer-reviewed human clinical trials

🟢Human Clinical Evidence

🟡Limited Human Evidence

🟠Mostly Animal Research

🔴Preclinical / Laboratory

This information is for educational and research purposes only. It does not constitute medical advice. Always consult a qualified healthcare professional before making any health decisions.